Evidence map›Paper›PMID 38225177›Full record

ArticleArthritis care & research2024

Essential Fatty Acids and Osteoarthritis.

David T Felson, Devyani Misra, Michael LaValley, Margaret Clancy, Gabriela Rabasa, Alice Lichtenstein, Nirupa Matthan, James Torner, Cora E Lewis, Michael C Nevitt and 1 more

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Arthritis care & research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

David T FelsonBoston University, Boston, Massachusetts.ORCID 0000-0002-2668-2447
Devyani MisraBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-2881-7920
Michael LaValleyBoston University, Boston, Massachusetts.
Margaret ClancyBoston University, Boston, Massachusetts.
Gabriela RabasaBoston University, Boston, Massachusetts.ORCID 0000-0002-4446-8129
Alice LichtensteinTufts University, Boston, Massachusetts.
Nirupa MatthanTufts University, Boston, Massachusetts.
James TornerUniversity of Iowa, Iowa City.
Cora E LewisUniversity of Alabama at Birmingham.
Michael C NevittUniversity of California, San Francisco.
MOST Study Investigators
Boston University · USTufts University · USBeth Israel Deaconess Medical Center · USUniversity of Alabama at Birmingham · USUniversity of California, San Francisco · USUniversity of Iowa · US

Funding

Southern All of Us NetworkOT2OD026548 · OD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FOUAD, MONA N., KORF, BRUCE R · 2018 to 2023
$60.5M
Project 3: Intraarticular MineralizationU19AG076471 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI TUHINA NEOGI · 2023 to 2026
$49.0M
Multicenter Osteoarthritis Study (MOST) Second RenewalU01AG019069 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NEVITT, MICHAEL C · 2001 to 2020
$21.7M
Multicenter Osteoarthritis Study (MOST) Second Renewal: Iowa Clinical CenterU01AG018832 · NIA · UNIVERSITY OF IOWA · PI SEGAL, NEIL A, TORNER, JAMES C · 2001 to 2020
$14.1M
Multicenter Osteoarthritis Study (MOST) Second Renewal - Boston UniversityU01AG018820 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FELSON, DAVID TOBIN · 2001 to 2019
$13.6M
Multicenter Osteoarthritis Study (MOST) Second Renewal - UAB Clinical CenterU01AG018947 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LEWIS, CORA E · 2001 to 2020
$13.2M
Research and Evaluation Support Core Unit (RESCU Core)P30AR072571 · NIAMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Michael Paul Lavalley · 2019 to 2026
$6.9M
Fats, Fiber and OsteoarthritisR01AR071950 · NIAMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FELSON, DAVID TOBIN · 2017 to 2020
$2.2M
Manchester Musculoskeletal NIHR Biomedical Research CentreNational Institute for Health Research (NIHR)NIAMS NIH HHS P30 AR072571NIAMS NIH HHS R01 AR071950NIA NIH HHS U01 AG018820NIA NIH HHS U01 AG018832NIA NIH HHS U01 AG018947NIA NIH HHS U01 AG019069NIA NIH HHS U19 AG076471NIH HHS AR-P30-072571NIH HHS P30-AR-072571NIH HHS R01-AR-071950NIH HHS U01-AG-18820NIH HHS U01-AG-18832NIH HHS U01-AG-18947NIH HHS U01-AG-19069NIH HHS U19-AG-076471
6 · The paper itself

Abstract

objectiveInflammation worsens joint destruction in osteoarthritis (OA) and aggravates pain. Although n-3 fatty acids reduce inflammation, different n-3 fatty acids have different effects on inflammation and clinical outcomes, with eicosapentaenoic acid (EPA) having the strongest effect. We examined whether specific essential fatty acid levels affected the development of OA.

methodsWe studied participants from the Multicenter Osteoarthritis Study (MOST) at risk of developing knee OA. As part of MOST, participants were asked repeatedly about knee pain, and knee radiographs and magnetic resonance images (MRIs) were obtained. Using baseline fasting samples, we analyzed serum fatty acids with standard assays. After excluding participants with baseline OA, we defined two sets of cases based on their status through 60 months' follow-up: those developing incident radiographic OA and those developing incident symptomatic OA (knee pain and radiographic OA). Controls did not develop these outcomes. Additionally, we examined worsening of MRI cartilage damage and synovitis and worsening knee pain and evaluated the number of hand joints affected by nodules. In regression models, we tested the association of each OA outcome with levels of specific n-3 and n-6 fatty acids, adjusting for age, sex, body mass index, education, physical activity, race, baseline pain, smoking, statin use, and depressive symptoms.

resultsWe studied 363 cases with incident symptomatic knee OA and 295 with incident radiographic knee OA. The mean age was 62 years (59% women). We found no associations of specific n-3 fatty acid levels, including EPA, or of n-6 fatty acid levels with incident OA (eg, for incident symptomatic knee OA, the odds ratio per SD increase in EPA was 1.0 [95% confidence interval 0.87-1.17]). Results for other OA outcomes also failed to suggest a protective effect of specific n-3 fatty acids with OA outcomes.

conclusionWe found no association of serum levels of EPA or of other specific n-3 fatty acids or n-6 fatty acids with risk of incident knee OA or other OA outcomes.

Indexed as

Magnetic Resonance ImagingOsteoarthritis, KneeAgedBiomarkersEicosapentaenoic AcidFatty Acids, EssentialFatty Acids, Omega-3Fatty Acids, Omega-6FemaleHumansIncidenceKnee JointMaleMiddle AgedRisk FactorsUnited StatesBiomarkersEicosapentaenoic AcidFatty Acids, EssentialFatty Acids, Omega-3Fatty Acids, Omega-6

Identifiers

PMID38225177
PMCPMC11132918
OpenAlexW4390892564

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.